glp-1 manufacturing news today Drug Manufacturing: Expansion & Tech Transfer 💊 In the News 🌍

2024 JAMA Ophthalmology Study Findings The landmark Harvard Medical School study published in JAMA Ophthalmology in July 2024 provided the first rigorous scientific evidence linking semaglutide to elevated NAION risk analyzing 16,827 patients at Massachusetts Eye and Ear and revealing alarming risk multipliers that prompted global regulatory scrutiny

This can lead to improved weight loss results and better management of body composition

Eligibility criteria include specific BMI thresholds, presence of comorbidities such as type 2 diabetes or cardiovascular disease, and previous weight loss attempts

Irwin N, McClean PL, OHarte FP, Gault VA, Harriott P, Flatt PR